<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169857</url>
  </required_header>
  <id_info>
    <org_study_id>X05321</org_study_id>
    <secondary_id>1003010960</secondary_id>
    <nct_id>NCT01169857</nct_id>
  </id_info>
  <brief_title>Velcade for Proliferative Lupus Nephritis</brief_title>
  <official_title>Velcade for Proliferative Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to test the safety and efficacy of Velcade to induce remission in
      WHO class III/IV/V lupus nephritis that are refractory to standard medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory single center, open-label, single treatment group assignment, safety, and
      efficacy study will enroll 14 patients with WHO class III/IV/V lupus nephritis. Subjects will
      receive 12 doses of Velcade to induce clinical remission.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants were enrolled.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>1 year</time_frame>
    <description>Quantification of 24 hr urinary protein.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>1 year</time_frame>
    <description>Serum creatinine and GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lupus activity score</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of SELENA-SLEDAI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lupus Nephritis</condition>
  <condition>Proteinuria</condition>
  <condition>Hematuria</condition>
  <arm_group>
    <arm_group_label>Velcade Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.</description>
    <arm_group_label>Velcade Therapy</arm_group_label>
    <other_name>Bortezomib</other_name>
    <other_name>Proteasome inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ACR criteria for lupus (minimum 4 out of 11).

          2. Biopsy proven WHO class III or IV or V lupus nephritis with clinical activity.

          3. GFR must be greater or equal to 30 cc/min/1.73 m2.

          4. Proteinuria must exceed 1000 mg per day except for WHO class V lupus nephritis, daily
             proteinuria must be greater or equal to 2000 mg.

          5. Primary therapy for active disease must have been given at least 6 months prior to
             protocol enrollment for WHO lupus III/IV.

        Exclusion Criteria:

          1. Serum creatinine of more than 3.0 mg/dL on repeated testing.

          2. Greater than 50% fibrosis on renal biopsy.

          3. Platelet count of less than 30× 109/L.

          4. Absolute neutrophil count of less than 1.0 × 109/L.

          5. Greater than or equal to Grade 1 peripheral neuropathy.

          6. Myocardial infarction within 6 months prior to enrollment or New York Heart
             Association (NYHA) Class III or IV heart failure.

          7. Hypersensitivity to Velcade, boron or mannitol.

          8. Serious medical conditions and infections (including HIV, HCV, HBV) or psychiatric
             illness.

          9. Known history of untreated positive PPD.

         10. Serious complications from systemic lupus such as cerebral lupus and severe active
             infections.

         11. Diagnosed or treated for another malignancy within 3 years of enrollment.

         12. Greater than 1.5x upper limit of normal total bilirubin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choli Hartono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proliferative lupus nephritis</keyword>
  <keyword>WHO class III/IV/V lupus nephritis</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Hematuria</keyword>
  <keyword>Velcade</keyword>
  <keyword>SLE</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Proteasome inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Hematuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

